80 completed, 24 unknown, 19 terminated, 9 recruiting. 145 Phase 2, 30 Phase 1, 18 Phase 3.
Follow Paralysis: new trials by email Literature Review of Paralysis trials Research Report on Paralysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies NIO752, Placebo - Progressive Supranuclear Palsy, Corticobasal Degeneration | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 48 | 2026-10-23 | 2026-10-09 |
| Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI) Galantamine Hydrobromide Extended Release - Spinal Cord Injury, Traumatic Spinal Cord Injury | Phase 2 / Phase 3 | Recruiting | Northwell Health | 60 | 2026-10-15 | 2026-11-04 |
| Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy | Phase 1 / Phase 2 | Recruiting | Prabesh Kanel | 15 | 2026-10-01 | 2026-11-05 |
| Psilocybin to Treat Depression in Spinal Cord Injury Psilocybin (Usona Institute) - Spinal Cord Injury, Depression - Major Depressive Disorder | Phase 1 / Phase 2 | Recruiting | James J. Peters Veterans Affairs Medical Center | 30 | 2026-08-06 | 2026-08-10 |
| The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1 AADvac1, Matching Placebo - PSP - Progressive Supranuclear Palsy | Phase 2 | Enrolling by invitation | Adam Boxer | 146 | 2026-07-29 | 2026-11-05 |
| The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31 LM11A-31, Matching Placebo - PSP - Progressive Supranuclear Palsy | Phase 2 | Enrolling by invitation | Adam Boxer | 147 | 2026-07-29 | 2026-11-05 |
| The Progressive Supranuclear Palsy Clinical Trial Platform AADvac1, LM11A-31 - Progressive Supranuclear Palsy(PSP) | Phase 2 | Recruiting | Adam Boxer | 440 | 2026-07-29 | 2026-11-10 |
| Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary Tauopathies ARO-MAPT-SC, Placebo - Alzheimer Disease, Tauopathies | Phase 1 / Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 160 | 2025-11-18 | 2026-11-10 |
| Facilitating Neuroplastic Changes of Acute Stroke Survivors Motor relearning training, Passive stretching, Gamed-based active movement training - Stroke | Phase 1 / Phase 2 | Recruiting | University of Maryland, Baltimore | 68 | 2025-06-01 | 2026-07-23 |
| A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis. CIN-102 Dose 15mg, Placebo, CIN-102 Dose 10mg - Idiopathic Gastroparesis | Phase 2 | Completed | CinDome Pharma, Inc. | 416 | 2025-01-29 | 2026-07-13 |
| Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy Botulinum Toxin A (Botox ), Pyloromyotomy - Esophageal Cancer Surgery, Esophagectomy | Phase 2 / Phase 3 | Recruiting | The Cleveland Clinic | 170 | 2024-12-03 | 2026-02-25 |
| A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) FNP-223, Placebo - Progressive Supranuclear Palsy | Phase 2 | Active not recruiting | Ferrer Internacional S.A. | 241 | 2024-07-23 | 2025-10-15 |
| The Use of Dexamethasone in Total Thyroidectomy to Improve Voice Outcome and Hypocalcaemia Dexamethasone, Normal saline - Voice Change, Hypocalcemia | Phase 2 | Unknown | Tseung Kwan O Hospital, Hong Kong | 100 | 2024-07-01 | 2024-07-09 |
| The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism Nicotinamide Riboside, Placebo - Progressive Supranuclear Palsy, Multiple System Atrophy | Phase 2 | Recruiting | Haukeland University Hospital | 330 | 2024-03-05 | 2025-01-10 |
| AMX0035 and Progressive Supranuclear Palsy AMX0035, Placebo - Progressive Supranuclear Palsy, PSP | Phase 2 / Phase 3 | Completed | Amylyx Pharmaceuticals Inc. | 139 | 2023-12-21 | 2026-04-30 |
| Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 GV1001 Placebo, GV1001 1.12mg - Progressive Supranuclear Palsy | Phase 2 | Completed | GemVax & Kael | 67 | 2023-12-12 | 2025-11-21 |
| GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) GV1001 Placebo, GV1001 0.56mg, GV1001 1.12mg - Progressive Supranuclear Palsy | Phase 2 | Completed | GemVax & Kael | 78 | 2023-06-14 | 2026-02-10 |
| Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI) Ursolic Acid, Strength Training - Spinal Cord Injuries, Tetraplegia | Phase 2 | Completed | University of Miami | 10 | 2023-03-27 | 2025-05-21 |
| A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis CIN-102 Dose 15mg or 10mg, Placebo - Diabetic Gastroparesis | Phase 2 | Completed | CinDome Pharma, Inc. | 382 | 2023-03-27 | 2026-11-05 |
| Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) MELPIDA - Spasticity, Muscle, Microcephaly | Phase 1 / Phase 2 | Recruiting | Elpida Therapeutics SPC | 4 | 2023-02-15 | 2026-07-08 |
Showing 20 of 145. Sign in to see all of them.
Gastroparesis (50) · Supranuclear Palsy, Progressive (31) · Spinal Cord Injuries (24) · Quadriplegia (22) · Paraplegia (21) · Stroke (20) · Hemiplegia (18) · Diabetes Mellitus (13) · Vocal Cord Paralysis (5) · Vomiting (5) · Corticobasal Degeneration (4) · Multiple System Atrophy (4) · Muscle Spasticity (4) · Nausea (4)
Pathological Conditions, Signs and Symptoms (145) · Signs and Symptoms (145) · Neurologic Manifestations (143) · Nervous System Diseases (96) · Central Nervous System Diseases (81) · Brain Diseases (58) · Stomach Diseases (50) · Digestive System Diseases (49) · Gastrointestinal Diseases (49) · Cranial Nerve Diseases (39) · Eye Diseases (34) · Ocular Motility Disorders (34) · Ophthalmoplegia (34) · Neurodegenerative Diseases (33)
N-(3-fluorophenyl)-1-((4-(((3S)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine (6) · Metoclopramide (4) · Botulinum Toxins, Type A (3) · Buspirone (3) · Saline Solution (3) · Tablets (3) · AADvac1 (2) · Acupuncture Therapy (2) · Clinical Trials, Phase II as Topic (2) · Clinical Trials, Phase III as Topic (2) · Constraint Induced Movement Therapy (2) · Cysteamine (2) · Erythromycin (2) · LM11A-31 (2) · Laryngoplasty (2)
GlaxoSmithKline (6) · Mayo Clinic (4) · Tranzyme, Inc. (4) · US Department of Veterans Affairs (4) · Adam Boxer (3) · CinDome Pharma, Inc. (3) · Johns Hopkins University (3) · University of Florida (3) · VA Office of Research and Development (3) · AbbVie (2) · Amgen (2) · GemVax & Kael (2) · MetroHealth Medical Center (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · Royal Adelaide Hospital (2)
United States (87) · Germany (14) · Canada (12) · France (12) · United Kingdom (12) · Australia (11) · Sweden (8) · Italy (7) · Poland (7) · Spain (7) · Belgium (6) · Denmark (5) · Norway (5) · Israel (4) · Japan (4)
Adam Boxer, MD, PhD (3) · Anne-Marie Wills, MD (3) · Irene Litvan, MD (3) · Julio Rojas-Martinez, MD, PhD (3) · Christian Debry, MD (2) · Joseph T Hull, PhD (2) · Mouen Khashab, MD (2) · Sang Jae Kim (2) · Adam Boxer, M.D., PhD. (1) · Adil E Bharucha, MBBS, MD (1)
PMID 23848826, PMID 32301137, PMID 38825840, PMID 12052996, PMID 14568122, PMID 14578723, PMID 14617717, PMID 15273542, PMID 17385265, PMID 17904594, PMID 17965289, PMID 17981197, PMID 18358585, PMID 19074686, PMID 19618698, PMID 19651280, PMID 19694164, PMID 19926154, PMID 20012982, PMID 20100698, PMID 20435515, PMID 21107104, PMID 21372246, PMID 21381984, PMID 21448576, PMID 21762873, PMID 22525310, PMID 23079762, PMID 23622977, PMID 23700789, PMID 23844986, PMID 24119615, PMID 24419482, PMID 24438512, PMID 24873720, PMID 25115420, PMID 25527487, PMID 25576687, PMID 26924243, PMID 27055601, PMID 27136096, PMID 27160012, PMID 27429037, PMID 27476581, PMID 28040257, PMID 28436538, PMID 28760384, PMID 29111115, PMID 29228183, PMID 29278279
R01AG085029 (3), 2016 (2), 2023 (2), U01DK073974 (2), U01DK073975 (2), U01DK073983 (2), U01DK074007 (2), U01DK074035 (2), 2014 (1), 2017 (1), K01HD069504 (1), K24HD054600 (1), P01DK068055 (1), R01DK122280 (1), R01NS061304 (1)